4D MOLECULAR THERAPEUTICS IN

CEO David Kirn sells 26,842 shares of 4D Molecular Therapeutics at $10.23—plan‑driven, not distress. Investors should monitor liquidity, price, and pipeline news.

CEO David Kirn’s 10b‑5‑1 sell of 12,415 4D Molecular shares shows disciplined liquidity management—no sign of distress, just routine insider trading.

Explore how CEO David Kirn’s 10(b)(5) sales affect 4D Molecular Therapeutics’ share price, market sentiment, and future confidence.

4D Molecular’s insider buying under a 10b‑5 plan shows confidence, with CEO Bizily Scott snapping up shares at discount while selling options to lock gains.

CEO’s 10b‑5‑1 sale of 115k shares signals liquidity‑management, not a warning—insider buying backs confidence in 4D’s growth.

Insider sale of 1,922 shares by 4D Molecular Therapeutics CEO under a 10b5‑1 plan shows cautious confidence, not a red flag.